Search academic texts

Information × Registration Number 0209U005125, 0106U002361 , R & D reports Title To create the all-nation system of differentiated approach to treatment of patients with malignant lymphoproliferative disease by stratification against the background of standardized diagnostics popup.stage_title Head Chumak Anatolii Andriiovych, Доктор медичних наук Registration Date 16-01-2009 Organization State Institution "Research Center for Radiation Medicine of Academy of Medical Sciences of Ukraine" popup.description2 The object of study - 234 chronic lymphoproliferative disorders (CLPD) patients, including 213 chronic lymphoid leukemia (CLL) patients, 7 - the other CLPD, 4 - polyclonal lymphocytosis. The approbation of different types of primers, their combinations and schemes for investigation of immunoglobulin heavy chain genes (VH) were fulfilled. The optimal test-system for evaluation of mutation status of VH genes was presented. It was established that 34.9% of CLL patients expressed VH1 genes (among them VH1-69 was the most frequent), 43.9% of patients expressed VH3 genes (among them VH3-07, VH3-09, VH3-21, VH3-30, VH3-33) and 19.2% of patients expressed VH4 genes (first of all, VH4-34, and VH4-59). The most of patients (70.7%) had unmutated status of VH genes, that is unfavorable features of disease and connected with late diagnosis. Cell response on ionizing radiation (IR) evaluated by cell survival test and expression of p53, p21, MDM2 in cell lysates by Western-blot analysis was made in 51 CLL patients.Four types of cell response were revealed, three of them were connected with anomalies of p53 and ATM genes (mutations, deletions). p53 gene mutations were found and confirmed by direct sequence in4 patients. Normal cell response was found in the most of CLL patients (78.4%). Atypical cell response was associated with tduration of treatment and progression (in previously treated patients) and younger age, B-symptoms and CD38 expression (in untreated patients). Prognostic significance of atypical cell response on IR correlated with poor response on therapy. The patent of Ukraine № 31408 UА "The method of risk group determination for development of cytomegalovirus infection in CLL patients" was prepared. Prognostic factors that influence on overall, progression-free, and treatment-free survival were revealed. The stratification of CLL patirnts on f low, intermediate, and high risk group was made. It is necessary for optimization of treatment protocols. Methodical recommendations "Prognostic factors in chroniclymphocytic leukemia" were prepared. Product Description popup.authors popup.nrat_date 2020-04-02 Close